Mark Corrigan, MD


         Dr. Corrigan is a leader in life sciences.  Following his academic training in psychiatry and appointment to the faculty of the University of North Carolina, Dr. Corrigan spent a decade at Pharmacia rising to positions of increasing responsibility ultimately as Group VP for Clinical Research and Experimental Medicine. He then joined Sepracor, a mid-size specialty pharma company in the C suite and leading Research and Development.  Following a successful exit, Dr. Corrigan took his first CEO position at Zalicus leading the company through a merger.  Subsequent to that effort Dr. Corrigan co-founded a rare diseases company, Tremeau Pharmaceuticals and following its acquisition, he assumed the leadership of Correvio Pharma, a publicly traded, global, commercial stage company leading their acquisition by Advanz Pharma in 2021. Dr. Corrigan currently serves as Strategic Advisor to Ceretype, President of R&D at Tremeau Pharmaceuticals, Board member at Wave Biosciences and Nabriva Therapeutics and Chairman of Exacis Therapeutics and Chairman of Elios Therapeutics. He is a visiting Professor of Psychiatry at Brigham and Women’s Hospital.

Follow us

(c) 2022 Ceretype Neuromedicine

  • LinkedIn
  • Twitter